Feature | December 09, 2014

Near-Infrared Spectroscopy May Predict Risk of Future Heart Attack and Stroke

Study using Infraredx's TVC Imaging System to identify lipid-core plaque that can lead to major adverse cardiac and cerebrovascular events

near-infrared spectroscopy, NIRS, heart attack, stroke, Infraredx, TVC

December 9, 2014 — A study published in the Journal of the American College of Cardiology (JACC) shows intravascular near-infrared spectroscopy (NIRS) can identify lipid core-containing plaques, implicated in most heart attacks. The study shows the technology might be used as a means to predict the risk of future major adverse cardiac and cerebrovascular events (MACCE).

In the study, patients who presented with symptoms associated with limited blood supply to the heart also underwent NIRS imaging to evaluate the Lipid Core Burden Index (LCBI) in an artery that was not directly implicated in causing their symptoms. The results, which were published online on Dec. 8 and will appear in the Dec. 16 print edition of JACC, demonstrated that patients with an LCBI ? 43 in a non-culprit artery had a fourfold risk of MACCE such as heart attack or stroke within the following year. In addition, the study concluded that non-culprit vessel LCBI reflects vascular vulnerability of the larger coronary tree.

Lipid-core plaque is a type of fatty coronary artery plaque suspected to be prone to rupture, which leads to the formation of blood clots that can cause heart attacks. Only NIRS can detect lipid-core plaque and provide a quantitative measurement in the form of an LCBI. Intravascular NIRS is commercially available through the TVC Imaging System from Infraredx Inc., a U.S. Food and Drug Administration (FDA)-cleared dual-modality imaging system capable of rapidly, specifically and reliably identifying lipid-core plaques using NIRS and providing vessel structure information using enhanced intravascular ultrasound (IVUS).

“Our findings suggest that the use of NIRS imaging to identify and quantify lipid-core plaque in the non-culprit arteries, which would otherwise remain undetected by coronary angiography, could be a viable tool to assess the vascular vulnerability of the larger coronary tree,” said Rohit M. Oemrawsingh, M.D., M.Sc, the study’s first author at the Thoraxcenter, department of cardiology, Erasmus MC, Rotterdam, the Netherlands.

The ATHEROREMO-NIRS Study, a sub-study of the European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO), is a prospective, single-center, observational study that enrolled 203 patients referred for coronary angiography due to stable angina (chest pain) or an acute coronary syndrome (ACS), a combination of symptoms resulting from the blockage of blood supply to the heart. NIRS imaging was performed and an LCBI measurement was obtained for a pre-defined segment of a non-culprit coronary artery that was at least 40 mm in length and with < 50 percent stenosis confirmed by angiography. The primary endpoint was the incidence of MACCE, defined as all-cause mortality, non-fatal ACS, stroke and unplanned coronary revascularization during one-year follow-up.

The research team hopes that the ongoing Lipid-Rich Plaque Study and PROSPECT II/ABSORB Study will provide further validation of their results. 

For more information: www.infraredx.com

Related Content

News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
Subscribe Now